• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

FDA Grants CAR T-Cell Therapy NXC-201 Orphan Drug Designation for Fatal Multiple Myeloma

by | Aug 23, 2023 | Myeloma News

Source: Pharmacy Times articles During the phase 1b/2 trials, CAR T-cell therapy demonstrated significant and clinical survival benefits. Read More

Microbiota dysbiosis after high-dose melphalan and autologous hematopoietic cell transplantation in multiple myeloma

by | Aug 22, 2023 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Long-term outcomes of allogeneic stem cell transplant in multiple myeloma

by | Aug 18, 2023 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level

by | Aug 17, 2023 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

by | Aug 15, 2023 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

FDA Grants Accelerated Approval to Elranatamab-bcmm for Relapsed or Refractory Multiple Myeloma

by | Aug 14, 2023 | Myeloma News

Source: Pharmacy Times articles Elranatamab-bcmm (Elrexfio; Pfizer) is a BCMA-CD3-targeted bispecific antibody approved for adults with relapsed or refractory multiple myeloma who were previously administered at least 4 lines of therapy that included a proteasome...
« Older Entries
Next Entries »

Recent Content

  • High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis
  • CAR-T cell therapy in Multiple Myeloma: current status and future challenges
  • Belantamab Mafodotin Achieves Secondary End Point for Treatment of Relapsed, Refractory Multiple Myeloma
  • Efficacy and safety of daratumumab for the treatment of refractory/relapsed multiple myeloma. A systematic review of meta-analyses
  • Cell surface marker heterogeneity in human myeloma cell lines for modeling of disease and therapy
  • A systematic review on the epidemiology and treatment options of multiple Myeloma in Asia
  • Blenrep-Based Combo Provides Survival Benefit in Relapsed/Refractory Multiple Myeloma
  • A systematic literature review on clonal evolution events preceding relapse in multiple myeloma
  • Efficacy and safety of teclistamab in relapsed or refractory multiple myeloma: a systematic review and meta-analysis
  • A systematic review and meta-analysis of carfilzomib-associated thrombocytopenia as an adverse event in patients with multiple myeloma
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT